Press about RVC

Experts: Those Who Increase Investment in IT Will Survive
The COVID-19 pandemic has plunged the global community into a position of universal confusion. Not a single country, including Russia, was fully equipped for this new challenge. A business forced to survive non-working days while maintaining employee benefits was in a difficult situation.
The ExoAtlant company, a spin-off of the portfolio company of the RVC ExoAtlet Biofund portfolio, tested an industrial exoskeleton jointly with the “Scientific Research Institute of Occupational Medicine named after Academician NF. Izmerov.” The study results showed the safety and effectiveness of the development in those areas of production where physical labor associated with lifting and holding weights is used.
In 2019, the Russian venture capital market grew in volume: According to DSight and E&Y, start-up investments exceeded $868 million. However, in 2020, the industry is likely to decline due to the pandemic, which put many business processes on a forced pause, and investment activity also decreased significantly. How can a start-up survive in such conditions?
Russian Venture Company, which supervises the development of the Competence Centers of the National Technological Initiative in the status of an operator, sums up the results of the first one and a half years of work of structures that were created to accelerate Russia's entry into the technology markets of the future.
The innovative industry also suffered from the crisis associated with COVID – 19: many start-ups were at risk. But there are those who managed to reformat their business in time for current needs. Ekaterina Petrova, Director of GenerationS Corporate Accelerator, spoke about successful examples from its practice.
One of the practical results of the Up Great technology contest READ // ABLE may become the introduction in the near future of technologies for processing the natural language of a person (NLP, Natural Language Processing) in the practice of schools and universities, the organizers of the online conference dedicated to the contest said.
Human Stem Cells Institute Subsidiary, Center for Genetics and Reproductive Medicine Genetico have concluded a license agreement with the Mount Sinai hospital (Icahn School of Medicine at Mount Sinai) for the right to use a highly specific antigen for coronavirus SARS-CoV-2 to develop and commercialize a product for testing infected and those who have survived COVID-19.
The technology business sees the crisis as not only a threat, but also an opportunity for growth. About a third of companies plan expansion — for example, projects in the field of medicine and logistics. Alexander Povalko, CEO of Russian Venture Company, told Rossiyskaya Gazeta about support measures that will compensate for some problems that have arisen and will help to support the expansion of companies.


1 2 3 4 5 ... 26 Next

Search by name:

Search by date:

Select date in calendar
Select date in calendar
Venue: